APO Research
Talk to an analyst

APO RESEARCH · REPORT

Diagnostic Nuclear Medicines

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Diagnostic Nuclear Medicines Market Outlook and Growth Opportunities 2026

20 December 2025194 pages

Choose your research edition.

Industry ResearchDiagnostic Nuclear Medicines Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Diagnostic Nuclear Medicines Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Diagnostic Nuclear Medicines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Diagnostic Nuclear Medicines Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Diagnostic Nuclear Medicines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Diagnostic Nuclear Medicines market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Diagnostic Nuclear Medicines is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Diagnostic Nuclear Medicines market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Diagnostic Nuclear Medicines market include Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, SIEMENS, Dongcheng and Eli Lilly, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Diagnostic Nuclear Medicines market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Diagnostic Nuclear Medicines and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Diagnostic Nuclear Medicines sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Diagnostic Nuclear Medicines market size, projected growth trends, production technologies, key applications, and end-use industries.

Diagnostic Nuclear Medicines Segment by Company

Bracco Imaging

Cardinal Health

Curium Pharma

GE Healthcare

Jubilant Pharma

Lantheus

SIEMENS

Dongcheng

Eli Lilly

Novartis

China Isotope & Radiation

Diagnostic Nuclear Medicines Segment by Type

Tc-99m

F-18

Other

Diagnostic Nuclear Medicines Segment by Application

Oncology

Cardiology

Other

Diagnostic Nuclear Medicines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Diagnostic Nuclear Medicines status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Diagnostic Nuclear Medicines market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Diagnostic Nuclear Medicines significant trends, drivers, influence factors in global and regions.

6. To analyze Diagnostic Nuclear Medicines competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diagnostic Nuclear Medicines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Diagnostic Nuclear Medicines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diagnostic Nuclear Medicines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Diagnostic Nuclear Medicines market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Diagnostic Nuclear Medicines industry.

Chapter 3: Detailed analysis of Diagnostic Nuclear Medicines manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Diagnostic Nuclear Medicines in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Diagnostic Nuclear Medicines in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Diagnostic Nuclear Medicines Industry Trends Table 2. Diagnostic Nuclear Medicines Industry Drivers Table 3. Diagnostic Nuclear Medicines Industry Opportunities and Challenges Table 4. Diagnostic Nuclear Medicines Industry Restraints Table 5. Global Diagnostic Nuclear Medicines Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Diagnostic Nuclear Medicines Revenue Share by Company (2021-2026) Table 7. Global Diagnostic Nuclear Medicines Sales Volume by Company (k units) & (2021-2026) Table 8. Global Diagnostic Nuclear Medicines Sales Volume Share by Company (2021-2026) Table 9. Global Diagnostic Nuclear Medicines Average Price (US$/unit) of Company (2021-2026) Table 10. Global Diagnostic Nuclear Medicines Company Ranking, (2024-2026) & (USD Million) Table 11. Global Diagnostic Nuclear Medicines Key Company Manufacturing Base & Headquarters Table 12. Global Diagnostic Nuclear Medicines Company, Product Type & Application Table 13. Global Diagnostic Nuclear Medicines Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Diagnostic Nuclear Medicines by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Tc-99m Table 18. Significant Companies of F-18 Table 19. Significant Companies of Other Table 20. Global Diagnostic Nuclear Medicines Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 21. Global Diagnostic Nuclear Medicines Sales Volume by Type (2021-2026) & (k units) Table 22. Global Diagnostic Nuclear Medicines Sales Volume by Type (2027-2032) & (k units) Table 23. Global Diagnostic Nuclear Medicines Sales Volume Share by Type (2021-2026) Table 24. Global Diagnostic Nuclear Medicines Sales Volume Share by Type (2027-2032) Table 25. Global Diagnostic Nuclear Medicines Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Diagnostic Nuclear Medicines Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Diagnostic Nuclear Medicines Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Diagnostic Nuclear Medicines Sales Value Share by Type (2021-2026) Table 29. Global Diagnostic Nuclear Medicines Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Oncology Table 31. Significant Companies of Cardiology Table 32. Significant Companies of Other Table 33. Global Diagnostic Nuclear Medicines Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 34. Global Diagnostic Nuclear Medicines Sales Volume by Application (2021-2026) & (k units) Table 35. Global Diagnostic Nuclear Medicines Sales Volume by Application (2027-2032) & (k units) Table 36. Global Diagnostic Nuclear Medicines Sales Volume Share by Application (2021-2026) Table 37. Global Diagnostic Nuclear Medicines Sales Volume Share by Application (2027-2032) Table 38. Global Diagnostic Nuclear Medicines Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Diagnostic Nuclear Medicines Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Diagnostic Nuclear Medicines Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Diagnostic Nuclear Medicines Sales Value Share by Application (2021-2026) Table 42. Global Diagnostic Nuclear Medicines Sales Value Share by Application (2027-2032) Table 43. Global Diagnostic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 44. Global Diagnostic Nuclear Medicines Sales by Region (2021-2026) & (k units) Table 45. Global Diagnostic Nuclear Medicines Sales Market Share by Region (2021-2026) Table 46. Global Diagnostic Nuclear Medicines Sales by Region (2027-2032) & (k units) Table 47. Global Diagnostic Nuclear Medicines Sales Market Share by Region (2027-2032) Table 48. Global Diagnostic Nuclear Medicines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Diagnostic Nuclear Medicines Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Diagnostic Nuclear Medicines Sales Value Share by Region (2021-2026) Table 51. Global Diagnostic Nuclear Medicines Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Diagnostic Nuclear Medicines Sales Value Share by Region (2027-2032) Table 53. Global Diagnostic Nuclear Medicines Market Average Price (US$/unit) by Region (2021-2026) Table 54. Global Diagnostic Nuclear Medicines Market Average Price (US$/unit) by Region (2027-2032) Table 55. Global Diagnostic Nuclear Medicines Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 56. Global Diagnostic Nuclear Medicines Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Diagnostic Nuclear Medicines Sales by Country (2021-2026) & (k units) Table 58. Global Diagnostic Nuclear Medicines Sales Market Share by Country (2021-2026) Table 59. Global Diagnostic Nuclear Medicines Sales by Country (2027-2032) & (k units) Table 60. Global Diagnostic Nuclear Medicines Sales Market Share by Country (2027-2032) Table 61. Global Diagnostic Nuclear Medicines Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Diagnostic Nuclear Medicines Sales Value Market Share by Country (2021-2026) Table 63. Global Diagnostic Nuclear Medicines Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Diagnostic Nuclear Medicines Sales Value Market Share by Country (2027-2032) Table 65. Bracco Imaging Company Information Table 66. Bracco Imaging Business Overview Table 67. Bracco Imaging Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 68. Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio Table 69. Bracco Imaging Recent Development Table 70. Cardinal Health Company Information Table 71. Cardinal Health Business Overview Table 72. Cardinal Health Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 73. Cardinal Health Diagnostic Nuclear Medicines Product Portfolio Table 74. Cardinal Health Recent Development Table 75. Curium Pharma Company Information Table 76. Curium Pharma Business Overview Table 77. Curium Pharma Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 78. Curium Pharma Diagnostic Nuclear Medicines Product Portfolio Table 79. Curium Pharma Recent Development Table 80. GE Healthcare Company Information Table 81. GE Healthcare Business Overview Table 82. GE Healthcare Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 83. GE Healthcare Diagnostic Nuclear Medicines Product Portfolio Table 84. GE Healthcare Recent Development Table 85. Jubilant Pharma Company Information Table 86. Jubilant Pharma Business Overview Table 87. Jubilant Pharma Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 88. Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio Table 89. Jubilant Pharma Recent Development Table 90. Lantheus Company Information Table 91. Lantheus Business Overview Table 92. Lantheus Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Lantheus Diagnostic Nuclear Medicines Product Portfolio Table 94. Lantheus Recent Development Table 95. SIEMENS Company Information Table 96. SIEMENS Business Overview Table 97. SIEMENS Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. SIEMENS Diagnostic Nuclear Medicines Product Portfolio Table 99. SIEMENS Recent Development Table 100. Dongcheng Company Information Table 101. Dongcheng Business Overview Table 102. Dongcheng Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Dongcheng Diagnostic Nuclear Medicines Product Portfolio Table 104. Dongcheng Recent Development Table 105. Eli Lilly Company Information Table 106. Eli Lilly Business Overview Table 107. Eli Lilly Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. Eli Lilly Diagnostic Nuclear Medicines Product Portfolio Table 109. Eli Lilly Recent Development Table 110. Novartis Company Information Table 111. Novartis Business Overview Table 112. Novartis Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. Novartis Diagnostic Nuclear Medicines Product Portfolio Table 114. Novartis Recent Development Table 115. China Isotope & Radiation Company Information Table 116. China Isotope & Radiation Business Overview Table 117. China Isotope & Radiation Diagnostic Nuclear Medicines Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio Table 119. China Isotope & Radiation Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Diagnostic Nuclear Medicines Distributors List Table 123. Diagnostic Nuclear Medicines Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Diagnostic Nuclear Medicines Product Image Figure 2. Global Diagnostic Nuclear Medicines Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Diagnostic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 4. Global Diagnostic Nuclear Medicines Sales (2021-2032) & (k units) Figure 5. Global Diagnostic Nuclear Medicines Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Diagnostic Nuclear Medicines Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Tc-99m Image Figure 10. F-18 Image Figure 11. Other Image Figure 12. Global Diagnostic Nuclear Medicines Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 13. Global Diagnostic Nuclear Medicines Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Diagnostic Nuclear Medicines Sales Volume Share by Type (2021-2032) Figure 15. Global Diagnostic Nuclear Medicines Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Diagnostic Nuclear Medicines Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Diagnostic Nuclear Medicines Sales Value Share by Type (2021-2032) Figure 18. Oncology Image Figure 19. Cardiology Image Figure 20. Other Image Figure 21. Global Diagnostic Nuclear Medicines Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 22. Global Diagnostic Nuclear Medicines Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Diagnostic Nuclear Medicines Sales Volume Share by Application (2021-2032) Figure 24. Global Diagnostic Nuclear Medicines Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Diagnostic Nuclear Medicines Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Diagnostic Nuclear Medicines Sales Value Share by Application (2021-2032) Figure 27. Global Diagnostic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 28. Global Diagnostic Nuclear Medicines Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Diagnostic Nuclear Medicines Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Diagnostic Nuclear Medicines Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Diagnostic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 32. North America Diagnostic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Diagnostic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Diagnostic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Diagnostic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Diagnostic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Diagnostic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 38. South America Diagnostic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Diagnostic Nuclear Medicines Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Diagnostic Nuclear Medicines Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Diagnostic Nuclear Medicines Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Diagnostic Nuclear Medicines Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Tc-99m
  • F-18
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Bracco Imaging
  • Cardinal Health
  • Curium Pharma
  • GE Healthcare
  • Jubilant Pharma
  • Lantheus
  • SIEMENS
  • Dongcheng
  • Eli Lilly
  • Novartis
  • China Isotope & Radiation

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Diagnostic Nuclear Medicines Sales Value (2021-2032)
  4. 1.2.2 Global Diagnostic Nuclear Medicines Sales Volume (2021-2032)
  5. 1.2.3 Global Diagnostic Nuclear Medicines Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Diagnostic Nuclear Medicines Market Dynamics
  1. 2.1 Diagnostic Nuclear Medicines Industry Trends
  2. 2.2 Diagnostic Nuclear Medicines Industry Drivers
  3. 2.3 Diagnostic Nuclear Medicines Industry Opportunities and Challenges
  4. 2.4 Diagnostic Nuclear Medicines Industry Restraints
3 Diagnostic Nuclear Medicines Market by Company
  1. 3.1 Global Diagnostic Nuclear Medicines Company Revenue Ranking in 2025
  2. 3.2 Global Diagnostic Nuclear Medicines Revenue by Company (2021-2026)
  3. 3.3 Global Diagnostic Nuclear Medicines Sales Volume by Company (2021-2026)
  4. 3.4 Global Diagnostic Nuclear Medicines Average Price by Company (2021-2026)
  5. 3.5 Global Diagnostic Nuclear Medicines Company Ranking (2024-2026)
  6. 3.6 Global Diagnostic Nuclear Medicines Company Manufacturing Base and Headquarters
  7. 3.7 Global Diagnostic Nuclear Medicines Company Product Type and Application
  8. 3.8 Global Diagnostic Nuclear Medicines Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Diagnostic Nuclear Medicines Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Diagnostic Nuclear Medicines Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Diagnostic Nuclear Medicines Market by Type
  1. 4.1 Diagnostic Nuclear Medicines Type Introduction
  2. 4.1.1 Tc-99m
  3. 4.1.2 F-18
  4. 4.1.3 Other
  5. 4.2 Global Diagnostic Nuclear Medicines Sales Volume by Type
  6. 4.2.1 Global Diagnostic Nuclear Medicines Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Diagnostic Nuclear Medicines Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Diagnostic Nuclear Medicines Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Diagnostic Nuclear Medicines Sales Value by Type
  10. 4.3.1 Global Diagnostic Nuclear Medicines Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Diagnostic Nuclear Medicines Sales Value by Type (2021-2032)
  12. 4.3.3 Global Diagnostic Nuclear Medicines Sales Value Share by Type (2021-2032)
5 Diagnostic Nuclear Medicines Market by Application
  1. 5.1 Diagnostic Nuclear Medicines Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Diagnostic Nuclear Medicines Sales Volume by Application
  6. 5.2.1 Global Diagnostic Nuclear Medicines Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Diagnostic Nuclear Medicines Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Diagnostic Nuclear Medicines Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Diagnostic Nuclear Medicines Sales Value by Application
  10. 5.3.1 Global Diagnostic Nuclear Medicines Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Diagnostic Nuclear Medicines Sales Value by Application (2021-2032)
  12. 5.3.3 Global Diagnostic Nuclear Medicines Sales Value Share by Application (2021-2032)
6 Diagnostic Nuclear Medicines Regional Sales and Value Analysis
  1. 6.1 Global Diagnostic Nuclear Medicines Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Diagnostic Nuclear Medicines Sales by Region (2021-2032)
  3. 6.2.1 Global Diagnostic Nuclear Medicines Sales by Region: 2021-2026
  4. 6.2.2 Global Diagnostic Nuclear Medicines Sales by Region (2027-2032)
  5. 6.3 Global Diagnostic Nuclear Medicines Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Diagnostic Nuclear Medicines Sales Value by Region (2021-2032)
  7. 6.4.1 Global Diagnostic Nuclear Medicines Sales Value by Region: 2021-2026
  8. 6.4.2 Global Diagnostic Nuclear Medicines Sales Value by Region (2027-2032)
  9. 6.5 Global Diagnostic Nuclear Medicines Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Diagnostic Nuclear Medicines Sales Value (2021-2032)
  12. 6.6.2 North America Diagnostic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Diagnostic Nuclear Medicines Sales Value (2021-2032)
  15. 6.7.2 Europe Diagnostic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Diagnostic Nuclear Medicines Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Diagnostic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Diagnostic Nuclear Medicines Sales Value (2021-2032)
  21. 6.9.2 South America Diagnostic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Diagnostic Nuclear Medicines Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Diagnostic Nuclear Medicines Sales Value Share by Country, 2025 VS 2032
7 Diagnostic Nuclear Medicines Country-level Sales and Value Analysis
  1. 7.1 Global Diagnostic Nuclear Medicines Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Diagnostic Nuclear Medicines Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Diagnostic Nuclear Medicines Sales by Country (2021-2032)
  4. 7.3.1 Global Diagnostic Nuclear Medicines Sales by Country (2021-2026)
  5. 7.3.2 Global Diagnostic Nuclear Medicines Sales by Country (2027-2032)
  6. 7.4 Global Diagnostic Nuclear Medicines Sales Value by Country (2021-2032)
  7. 7.4.1 Global Diagnostic Nuclear Medicines Sales Value by Country (2021-2026)
  8. 7.4.2 Global Diagnostic Nuclear Medicines Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Diagnostic Nuclear Medicines Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Diagnostic Nuclear Medicines Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Diagnostic Nuclear Medicines Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Bracco Imaging
  2. 8.1.1 Bracco Imaging Company Information
  3. 8.1.2 Bracco Imaging Business Overview
  4. 8.1.3 Bracco Imaging Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Bracco Imaging Diagnostic Nuclear Medicines Product Portfolio
  6. 8.1.5 Bracco Imaging Recent Developments
  7. 8.2 Cardinal Health
  8. 8.2.1 Cardinal Health Company Information
  9. 8.2.2 Cardinal Health Business Overview
  10. 8.2.3 Cardinal Health Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Cardinal Health Diagnostic Nuclear Medicines Product Portfolio
  12. 8.2.5 Cardinal Health Recent Developments
  13. 8.3 Curium Pharma
  14. 8.3.1 Curium Pharma Company Information
  15. 8.3.2 Curium Pharma Business Overview
  16. 8.3.3 Curium Pharma Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Curium Pharma Diagnostic Nuclear Medicines Product Portfolio
  18. 8.3.5 Curium Pharma Recent Developments
  19. 8.4 GE Healthcare
  20. 8.4.1 GE Healthcare Company Information
  21. 8.4.2 GE Healthcare Business Overview
  22. 8.4.3 GE Healthcare Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 GE Healthcare Diagnostic Nuclear Medicines Product Portfolio
  24. 8.4.5 GE Healthcare Recent Developments
  25. 8.5 Jubilant Pharma
  26. 8.5.1 Jubilant Pharma Company Information
  27. 8.5.2 Jubilant Pharma Business Overview
  28. 8.5.3 Jubilant Pharma Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Jubilant Pharma Diagnostic Nuclear Medicines Product Portfolio
  30. 8.5.5 Jubilant Pharma Recent Developments
  31. 8.6 Lantheus
  32. 8.6.1 Lantheus Company Information
  33. 8.6.2 Lantheus Business Overview
  34. 8.6.3 Lantheus Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Lantheus Diagnostic Nuclear Medicines Product Portfolio
  36. 8.6.5 Lantheus Recent Developments
  37. 8.7 SIEMENS
  38. 8.7.1 SIEMENS Company Information
  39. 8.7.2 SIEMENS Business Overview
  40. 8.7.3 SIEMENS Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 SIEMENS Diagnostic Nuclear Medicines Product Portfolio
  42. 8.7.5 SIEMENS Recent Developments
  43. 8.8 Dongcheng
  44. 8.8.1 Dongcheng Company Information
  45. 8.8.2 Dongcheng Business Overview
  46. 8.8.3 Dongcheng Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Dongcheng Diagnostic Nuclear Medicines Product Portfolio
  48. 8.8.5 Dongcheng Recent Developments
  49. 8.9 Eli Lilly
  50. 8.9.1 Eli Lilly Company Information
  51. 8.9.2 Eli Lilly Business Overview
  52. 8.9.3 Eli Lilly Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Eli Lilly Diagnostic Nuclear Medicines Product Portfolio
  54. 8.9.5 Eli Lilly Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Diagnostic Nuclear Medicines Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 China Isotope & Radiation
  62. 8.11.1 China Isotope & Radiation Company Information
  63. 8.11.2 China Isotope & Radiation Business Overview
  64. 8.11.3 China Isotope & Radiation Diagnostic Nuclear Medicines Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 China Isotope & Radiation Diagnostic Nuclear Medicines Product Portfolio
  66. 8.11.5 China Isotope & Radiation Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Diagnostic Nuclear Medicines Value Chain Analysis
  2. 9.1.1 Diagnostic Nuclear Medicines Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Diagnostic Nuclear Medicines Sales Mode & Process
  6. 9.2 Diagnostic Nuclear Medicines Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Diagnostic Nuclear Medicines Distributors
  9. 9.2.3 Diagnostic Nuclear Medicines Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst